Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab (EVAPOR)
Pneumococcal Infections, Lymphoma, Large B-Cell, Diffuse
About this trial
This is an interventional other trial for Pneumococcal Infections focused on measuring Lymphoma, pneumococcal vaccination, prime-boost, rituximab
Eligibility Criteria
Inclusion Criteria:
- De novo Diffuse Large B-Cell Lymphoma diagnostic (according 2016 World Health Organization (WHO) classification)
- Treatment decision by immunochemotherapy (R-CHOP)
- Age over 18 years old
- Negative pregnancy test at inclusion
- Active contraception at inclusion
- Free and informed consent procedure at inclusion
- Affiliation of the social security system
Exclusion Criteria:
- Patient with prior treatment by immunotherapy or chemotherapy
- Patient with prior treatment by debulking chemotherapy (COP)
- Patient with prior treatment by high-dose of corticosteroids
- Patients with an autoimmune disease
- Patients with a diffuse large B-cell lymphoma from transformation (follicular lymphoma, chronic lymphoid leukemia)
- Immunosuppressed patient with : asplenia, hereditary immunodeficiency disorder, infection by HIV, hepatitis B or C viruses, transplanted patient, hematopoietic stem cell transplantation, nephrotic syndrome, meningeal breach, cochlear implants.
- Patients vaccinated in the last month before inclusion
- Patients with prior transfusion of blood-products or immunoglobulins in the last three months before inclusion
- Patient with bleeding disorders or thrombopenia contraindicating intramuscular injection
- Patient with prior pneumococcal documented infection
- Patient with current pregnancy and/or breastfeeding
- Patient under curatorship or guardianship
Sites / Locations
- GYANRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Experimental
Single-dose before treatment
Single-dose after treatment
Double-dose before treatment
12 patients will receive a single-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection
12 patients will receive a singe-dose of prevenar three weeks after the beginning of the immunochemotherapy (R-CHOP) following two months later by pneumovax injection
12 patients will receive a double-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection.